VP1 capsid protein · SINGLE PROTEIN · Human rhinovirus sp.
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13VP1 capsid protein shows clinical signal disease relevance led by asthma. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q7T664. Start with asthma, then reuse UniProt Q7T664 as the stable protein anchor across project notes and exports.
Start with asthma, then reuse UniProt Q7T664 as the stable protein anchor across project notes and exports.
VP1 capsid protein shows clinical signal disease relevance led by asthma. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with asthma because it currently carries clinical signal support. Linked drugs include VAPENDAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGenome polyprotein
Review this target as VP1 capsid protein, mapped to UniProt Q7T664. ChEMBL maps the protein component as Genome polyprotein. Sequence length is 287 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats VP1 capsid protein as ChEMBL target CHEMBL3833484, mapped to UniProt Q7T664. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether VP1 capsid protein is the right protein anchor across sources, using UniProt Q7T664 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why asthma is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | VP1 capsid protein |
| Target Type | SINGLE PROTEIN |
| Organism | Human rhinovirus sp. |
| UniProt | Q7T664 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Genome polyprotein |
| UniProt Accession | Q7T664 |
| Component Type | Protein |
| Sequence Length | 287 aa |
Genome polyprotein
Review this target as VP1 capsid protein, mapped to UniProt Q7T664. ChEMBL maps the protein component as Genome polyprotein. Sequence length is 287 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
VP1 capsid protein shows clinical signal disease relevance led by asthma. 3 more disease programs remain visible in the same review block.
Start review with asthma because it currently carries clinical signal support. Linked drugs include VAPENDAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL29609 | 8.4 | EC50 | 4.0 | Clinical |
| CHEMBL4208180 | 7.77 | EC50 | 17.0 | Preclinical |
| CHEMBL4208286 | 7.3 | EC50 | 50.0 | Preclinical |
| CHEMBL4209270 | 6.89 | EC50 | 128.0 | Preclinical |
| CHEMBL4215079 | 6.75 | EC50 | 180.0 | Preclinical |
| CHEMBL4203308 | 6.72 | EC50 | 190.0 | Preclinical |
| CHEMBL4214859 | 6.7 | EC50 | 200.0 | Preclinical |
| CHEMBL4211585 | 6.6 | EC50 | 250.0 | Preclinical |
| CHEMBL4214159 | 6.6 | EC50 | 250.0 | Preclinical |
| CHEMBL4202881 | 6.4 | EC50 | 400.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 25 | 19 | 6.7 |
| single protein format | 5 | 0 | — |